ADA: Eli Lilly's stellar tirzepatide weight loss data tee up showdown with Novo Nordisk's Wegovy, analysts say

Eli Lilly, just weeks after snaring approval for dual GIP/GLP-1 med Mounjaro in Type 2 diabetes, is trumpeting its case for the nascent blockbuster in weight loss. The data likely portend a clash with Novo Nordisk’s obesity stalwart Wegovy, one group of analysts argues.